KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
C1-inhibitor Deficiency & Angioedema Workshop
The following poster presentations will take place during Poster Session I on Friday, May 30, from 3:45–5:30 pm CEST (9:45–11:30 am ET):
In their own words, patient perspectives on time to feeling in control of an HAE attack (P-18): Doug Jones, Anna Valerieva, Mar Guilarte, Neil Malloy, Sally van Kooten, Markus Heckmann, Markus Magerl.
Time to end of progression of hereditary angioedema attacks treated with sebetralstat (P-25): William R. Lumry, John Anderson, Jonathan A. Bernstein, Mauro Cancian, Danny M. Cohn, Henriette Farkas, Henry Li, James Hao, Michael Smith, Paolo Bajcic, Paul Audhya, Markus Magerl.
Impact of injectable HAE on-demand treatments on health-related quality of life: a patient and caregiver interview study (P-29): Patrick Yong, Aleena Banerji, Paula Busse, Timothy Craig, Sorena Kiani-Alikhan, Rebekah Hall, Siu Hing Lo, Caleb Dixon, Paul Audhya, Alice Wang, Tomaz Garcez.
The following oral presentation will take place during Scientific Session III on Saturday, May 31, from 2:30–2:45 pm CEST (8:30–8:45 am ET):
Effectiveness of sebetralstat for the on-demand treatment of mucosal hereditary angioedema attacks: interim analysis from KONFIDENT-S (O-29): Jonathan A. Bernstein, Emel Aygören-Pürsün, Vesna Grivcheva-Panovska, Inmaculada Martinez-Saguer, Danny M. Cohn, William R. Lumry, Marc A. Riedl, Andrea Zanichelli, Laurence Bouillet, Ya-Hsiu Chuang, Michael D. Smith, Christopher M. Yea, Paul K. Audhya, Henriette Farkas.
The following oral presentation will take place during Scientific Session V on Saturday, May 31, from 3:15–3:30 pm CEST (9:15–9:30 am ET):
Anxiety associated with hereditary angioedema attacks: results from the phase 3 KONFIDENT trial of oral sebetralstat (O-32): Timothy J. Craig, Emel Aygören-Pürsün, Jonathan A. Bernstein, Paula J. Busse, Teresa Caballero, Danny M. Cohn, Mar Guilarte, Henriette Farkas, Douglas H. Jones, Sorena Kiani-Alikhan, Michael E. Manning, Marcus Maurer, Marc A. Riedl, Sinisa Savic, H. James Wedner, Patrick F. K. Yong, Andrea Zanichelli, Erik Hansen, James Hao, Michael D. Smith, Christopher M. Yea, Paul K. Audhya, William R. Lumry.
The following poster presentation will take place during Poster Session II on Saturday, May 31, from 4:15–5:45 pm CEST (10:15–11:45 am ET):
Survey results from Italy, the US, UK, and France: Anxiety in patients using injectable on-demand treatments for hereditary angioedema attacks (P-32): Mauro Cancian, Alexis Bocquet, Paula J. Busse, Timothy Craig, Tariq El-Shanawany, Tomaz Garcez, Padmalal Gurugama, Rashmi Jain, Sorena Kiani-Alikhan, Maeve O'Connor, Cristine Radojicic, Sinisa Savic, Paola Triggianese, H. James Wedner, Patrick Yong, Andrea Zanichelli, Vibha Desai, Julie Ulloa, Sherry Danese, Paul K. Audhya, Sandra Christiansen.
KalVista is also sponsoring a pre-workshop symposium for healthcare professionals on Thursday, May 29, from 1:00–2:00 pm CEST (7:00–8:00 am ET) in the Magnolia room, titled ' Interplay Between On-Demand Treatment Guidelines and Clinical Trials in HAE.' Chaired by Dr. William Lumry, Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School and Medical Director of AARA Research Center, this symposium will highlight insights from Dr. Mauro Cancian (University Hospital of Padova, Italy) and Dr. Danny Cohn (University of Amsterdam, Netherlands), addressing the evolution of on-demand treatment guidelines in HAE, real-world challenges in guideline adherence, and advancements in clinical trial designs to support guideline adherence.
EAC
The following poster presentations will take place on Saturday, May 31, from 9:45–11:00 am ET:
Effectiveness of Sebetralstat for Severe or Very Severe Hereditary Angioedema Attacks in KONFIDENT-S: Henry Li, William R. Lumry, Michael E. Manning, Marc A. Riedl, James Wedner, James Hao, Michael D. Smith, Paul K. Audhya, Jonathan A. Bernstein.
On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Older Adults: Interim Analysis from KONFIDENT-S: Daniel F. Soteres, Alan P. Baptist, Jonathan A. Bernstein, Timothy Craig, William R. Lumry, James Hao, Michael D. Smith, Paolo Bajcic, Paul K. Audhya, Marc A. Riedl.
Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat: Daniel F. Soteres, William R. Lumry, John Anderson, Jonathan A. Bernstein, Mauro Cancian, Danny M. Cohn, Henriette Farkas, Henry Li, James Hao, Michael D. Smith, Paolo Bajcic, Paul K. Audhya, Markus Magerl.
Long-Term Prophylaxis Compliance and Healthcare Resource Utilization in Hereditary Angioedema: A Claims Database Analysis: Raffi Tachdjian, Daniel F. Soteres, Maeve O'Connor, Chirag Maheshwari, Alice Wang, Paul K. Audhya, Timothy Craig.
Links to all presentations can be found on the KalVista website under Publications.
About Sebetralstat
Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older, with ongoing studies exploring its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities.
For more information about KalVista, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 minutes ago
- Business Wire
Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced a collaboration with Novartis. Through this strategic collaboration, Atropos Health will build, train and evaluate multiple models to help streamline identification of people with a rare disease who have not yet been diagnosed, ultimately reducing time from symptom reporting to testing, diagnosis and treatment. The collaboration will specifically focus on paroxysmal nocturnal hemoglobinuria (PNH), a rare, serious blood disorder. Adults with PNH often experience lengthy diagnostic delays—many wait over a year, and some more than five—because the disease is rare and presents varied symptoms affecting multiple organs. 1,2 As a part of this collaboration, Atropos Health has developed an initial AI model for finding potential patients with PNH who have not yet been diagnosed, aimed to save critical time for both patients and providers by helping health systems accelerate appropriate diagnosis. The AI model is now available for integration into health systems. 'Building AI models tested and trained on high-quality real-world data is truly the next frontier in precision medicine,' said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. 'The accuracy of the models reduces the guesswork and patients who are able to get testing sooner provides a potentially life-changing experience. For providers and health systems, faster time to diagnosis and treatment equate to higher patient satisfaction.' The goal of the strategic collaboration is to build and publish patient-finding models aimed at reducing time from initial symptoms to testing, diagnosis and treatment. The models created by Atropos Health in connection with this collaboration will be implemented across health system members of the Atropos Evidence Network and be seamlessly integrated at the point of care to improve the provider and patient experience. Through this collaboration, Atropos Health will build models trained on real-world data (RWD) from the Atropos Evidence™ Network, which includes GENEVA OS ®. 'At Novartis, we are committed to delivering meaningful impact for patients. Accelerating diagnosis and treatment through AI and machine learning has the power to significantly improve patient outcomes by enabling faster access to appropriate care,' said Rodney Gillespie, Head of Oncology, Novartis US. 'Our collaboration with Atropos Health to develop an AI model for identifying PNH embodies this commitment as it advances precision health, potentially enabling earlier diagnosis and timely care, reducing delays that can greatly affect patients' lives.' About paroxysmal nocturnal hemoglobinuria (PNH) PNH is a rare, chronic and serious complement-mediated blood disorder 3. People with PNH have an acquired mutation in some of their hematopoietic stem cells (which are located in the bone marrow and can grow and develop into red blood cells [RBCs], white blood cells and platelets) that causes them to produce RBCs that are susceptible to premature destruction by the complement system. 4 It is estimated that approximately 10-20 people per million worldwide live with PNH. Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old. 5,6 Today's announcement follows Atropos Health's AI model training capabilities released earlier this year. Atropos Evidence Network membership benefits include the ability to leverage the network to deliver AI models to clinicians. Atropos Health is collaborating with Arcadia to help leading healthcare organizations deliver the latest care protocols and advanced precision medicine at scale. The partnership enables healthcare providers to accelerate clinical decision-making with actionable, AI-powered insights at the point of care using the combination of real-world evidence (RWE) and longitudinal patient records to improve outcomes and drive high-value, low-cost care. Healthcare organizations are also engaged with Atropos Health on leveraging AI for precision medicine, and building MOTOR, CLMBR and Foundation models on the Atropos Evidence Network. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth. _________________________ 1 Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8. PMID: 33356781; PMCID: PMC10408416 2 Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S. Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematol Rep. 2018 Mar 29;10(1):7523. doi: 10.4081/hr.2018.7523. PMID: 29721255; PMCID: PMC5907647. 3 Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348. 4 Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. 5 Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. 6 Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3-11. Expand
Business Wire
2 minutes ago
- Business Wire
Cynosure Lutronic Announces U.S. Clearance of the XERF™ Device, Redefining the Future
WESTFORD, Mass.--(BUSINESS WIRE)--Cynosure Lutronic, a global leader in energy-based medical aesthetic devices, is proud to announce that its XERF™ system, an innovative radiofrequency (RF) technology for skin tightening, has received clearance from the U.S. Food and Drug Administration. The XERF system is a groundbreaking, non-invasive solution for skin revitalization that tightens skin without the need for numbing, needles, or downtime, and is safe for all skin types. Key Features: World's First Single Shot, Multifrequency Monopolar RF Technology: This innovation combines 6.78 MHz and 2 MHz frequencies, enabling providers to precisely deliver energy at multiple tissue depths, effectively heating the fibrous septa to generate both immediate and lasting skin tightening results. Wave Fit™ Pulse and Advanced Integrated Cryogen Delivery (ICD) Cooling Technology: These advanced technologies work in tandem to regulate energy delivery and maintain optimal surface temperature, ensuring a comfortable treatment without the need for numbing. Innovative Spider Pattern Tip: Designed to reduce skin edge effects, this unique tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety. 'Securing clearance for the XERF device in the U.S. marks a major milestone for Cynosure Lutronic as we accelerate our growth across North America,' said Lowinn Kibbey, President, North America at Cynosure Lutronic. 'The U.S. market represents one of the largest and most dynamic aesthetics markets in the world, and we're proud to now offer patients and providers access to a breakthrough skin-tightening solution that delivers powerful results with a more comfortable, non-invasive experience.' 'As a fellowship-trained cosmetic dermatologist, we prioritize treatments in our clinic that can consistently deliver results with minimal risk and downtime. The XERF system incorporates the newest technology to safely deliver energy deeper down in the skin, while offering intelligent cooling for superior protection and patient comfort,' said Jordan V. Wang, MD, MBE, MBA, who is the Medical Director of Laser & Skin Surgery Center of Pennsylvania. Industry Milestone and Impact The XERF device launched in 2024 and is currently sold in Korea, Japan, Hong Kong and Canada. For more information, please visit About Cynosure Lutronic, Inc With over 30 years of combined innovation and action as the global leader in energy-based devices and superior medical aesthetic treatments, Cynosure Lutronic enables dermatologists, plastic surgeons, medical spas, and other healthcare practitioners to deliver non-invasive and minimally invasive procedures to their patients. Committed to research and development at the forefront of aesthetic technology, Cynosure Lutronic now proudly offers the most extensive portfolio of aesthetic devices in the industry, providing its customers with a more comprehensive range of solutions for skin resurfacing and revitalization, hair removal, vascular lesion treatment, skin toning, and body contouring. Cynosure Lutronic sells its products globally through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, and through international distributors in approximately 130 other countries. For more information, please visit The XERF™ device is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. All instances of the term 'skin tightening' are used to describe tightening effects that occur via soft tissue coagulation. Dr. Jordan Wang is a paid consultant of Cynosure Lutronic.
Business Wire
2 minutes ago
- Business Wire
GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic
BUSINESS WIRE)-- GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic ® (semaglutide) and Wegovy ® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic ® has been made available to patients at this self-pay price. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' said Wendy Barnes, President and Chief Executive Officer of GoodRx. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them. It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' In the last year, almost 17 million people came to GoodRx looking for savings and information on GLP-1 medications, a 22% increase from the previous year. Now, GoodRx is poised to more effectively meet this growing demand by leveraging the extensive reach and scale of its trusted platform to deliver savings directly to patients who need them. This collaboration represents a significant milestone in improving access and affordability of these important, authentic, FDA-approved medications. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic ® self-pay offer for type 2 diabetes patients at an unprecedented price.' Healthcare professionals are increasingly prescribing these groundbreaking medications to support patients diagnosed with type 2 diabetes or obesity—yet insurance coverage remains a challenge for many seeking treatment, especially those seeking obesity medications. For example, GoodRx research shows 19 million people lack coverage for any GLP-1s prescribed for weight loss. By filling the gaps in insurance coverage, GoodRx is playing a critical role in reducing friction in the system and helping accelerate speed to therapy so consumers can benefit from these critical treatments. Starting today, eligible patients can use GoodRx to self-pay for Ozempic ® and Wegovy ® pens for $499-per-month at over 70,000 retail pharmacies nationwide. To learn more, visit: or About GoodRx GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications. GoodRx periodically posts information that may be important to investors on its investor relations website at We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the 'SEC') and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release. GoodRx Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our offerings to consumers, GoodRx, Novo Nordisk and other pharmaceutical manufacturers. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
